Substantial evidence suggests that chronic hyperuricemia is an independent risk factor for hypertension, metabolic syndrome, chronic kidney disease and cardiovascular disease [1,2]. However, whether lowering serum UA can improve cardiovascular and renal outcomes, and what therapeutic mechanism of action could provide more clinical benefits to patients, is still a matter of discussion. Evidence from observational studies suggests possible cardiovascular benefits associated with ULT, in particular for the XO-inhibitors, while the evidence from randomized controlled trials is scarce and somewhat conflicting [2].
